Published in J Am Coll Cardiol on February 26, 2008
Advanced Cardiac Imaging To Predict Embolic Stroke On Brain MRI: A Pilot Study | NCT04769310
A new risk scheme to predict warfarin-associated hemorrhage: The ATRIA (Anticoagulation and Risk Factors in Atrial Fibrillation) Study. J Am Coll Cardiol (2011) 5.06
The net clinical benefit of warfarin anticoagulation in atrial fibrillation. Ann Intern Med (2009) 4.71
Impact of proteinuria and glomerular filtration rate on risk of thromboembolism in atrial fibrillation: the anticoagulation and risk factors in atrial fibrillation (ATRIA) study. Circulation (2009) 2.18
Moving the tipping point: the decision to anticoagulate patients with atrial fibrillation. Circ Cardiovasc Qual Outcomes (2010) 2.17
Association of left atrial fibrosis detected by delayed-enhancement magnetic resonance imaging and the risk of stroke in patients with atrial fibrillation. J Am Coll Cardiol (2011) 1.63
Should patient characteristics influence target anticoagulation intensity for stroke prevention in nonvalvular atrial fibrillation?: the ATRIA study. Circ Cardiovasc Qual Outcomes (2009) 1.29
MRI of the left atrium: predicting clinical outcomes in patients with atrial fibrillation. Expert Rev Cardiovasc Ther (2011) 1.17
Device-detected atrial fibrillation and risk for stroke: an analysis of >10,000 patients from the SOS AF project (Stroke preventiOn Strategies based on Atrial Fibrillation information from implanted devices). Eur Heart J (2013) 1.17
A new risk scheme to predict ischemic stroke and other thromboembolism in atrial fibrillation: the ATRIA study stroke risk score. J Am Heart Assoc (2013) 1.14
Impact of the CHA2DS2-VASc score on anticoagulation recommendations for atrial fibrillation. Am J Med (2012) 1.13
Use of anticoagulants in elderly patients: practical recommendations. Clin Interv Aging (2009) 1.04
The CHADS2 score predicts ischemic stroke in the absence of atrial fibrillation among subjects with coronary heart disease: data from the Heart and Soul Study. Am Heart J (2011) 1.03
Differences and time trends in drug treatment of atrial fibrillation in men and women and doctors' adherence to warfarin therapy recommendations: a Swedish study of prescribed drugs in primary care in 2002 and 2007. Eur J Clin Pharmacol (2012) 0.92
Performance of stroke risk scores in older people with atrial fibrillation not taking warfarin: comparative cohort study from BAFTA trial. BMJ (2011) 0.90
CHADS(2) score is predictive of left atrial thrombus on precardioversion transesophageal echocardiography in atrial fibrillation. Am J Cardiovasc Dis (2011) 0.89
Choices in the use of ICD-9 codes to identify stroke risk factors can affect the apparent population-level risk factor prevalence and distribution of CHADS2 scores. Am J Cardiovasc Dis (2012) 0.88
Neighborhood deprivation and warfarin, aspirin and statin prescription - A cohort study of men and women treated for atrial fibrillation in Swedish primary care. Int J Cardiol (2015) 0.88
Stroke prevention in atrial fibrillation: understanding the new oral anticoagulants dabigatran, rivaroxaban, and apixaban. Thrombosis (2012) 0.87
Thromboembolic event rate in paroxysmal and persistent atrial fibrillation: data from the GISSI-AF trial. BMC Cardiovasc Disord (2013) 0.86
Challenges in the classification of atrial fibrillation. Nat Rev Cardiol (2010) 0.83
A cluster-randomized controlled trial of a computerized antithrombotic risk assessment tool to optimize stroke prevention in general practice: a study protocol. BMC Health Serv Res (2014) 0.81
Impact of CHADS(2) Score on Neurological Severity and Long-Term Outcome in Atrial Fibrillation-Related Ischemic Stroke. J Clin Neurol (2012) 0.81
Atrial fibrillation, elevated troponin, ischemic stroke and adverse outcomes: understanding the connection. Clin Res Cardiol (2013) 0.81
Untreated atrial fibrillation in the United Kingdom: Understanding the barriers and treatment options. J Saudi Heart Assoc (2014) 0.80
Body mass index and risk of left atrial thrombus in patients with atrial fibrillation. Am J Cardiol (2009) 0.80
Patient Preferences for Oral Anticoagulation Therapy in Atrial Fibrillation: A Systematic Literature Review. Patient (2017) 0.79
Does CHA2DS2-VASc improve stroke risk stratification in postmenopausal women with atrial fibrillation? Am J Med (2013) 0.79
Stroke and bleeding risk in atrial fibrillation. Korean Circ J (2014) 0.78
Stroke in women. Nutr Metab Cardiovasc Dis (2010) 0.78
Antithrombotic therapy for the treatment of atrial fibrillation in the elderly. J Interv Card Electrophysiol (2009) 0.77
Warfarin treatment and risk of stroke among primary care patients with atrial fibrillation. Scand Cardiovasc J (2016) 0.77
Atrial fibrillation in heart failure: stroke risk stratification and anticoagulation. Heart Fail Rev (2014) 0.76
The use of cardiac magnetic resonance imaging in the diagnostic workup and treatment of atrial fibrillation. Cardiol Res Pract (2012) 0.76
Intensity of Left Atrial Spontaneous Echo Contrast as a Correlate for Stroke Risk Stratification in Patients with Nonvalvular Atrial Fibrillation. Sci Rep (2016) 0.75
Guideline adherence in antithrombotic treatment after concomitant ablation surgery in atrial fibrillation patients. Interact Cardiovasc Thorac Surg (2013) 0.75
Risk stratification of patients with atrial fibrillation: Biomarkers and other future perspectives. World J Cardiol (2012) 0.75
Watchman Device: Left Atrial Appendage Closure For Stroke Prophylaxis In Atrial Fibrillation. J Atr Fibrillation (2014) 0.75
Stroke Prevention in Atrial Fibrillation. J Atr Fibrillation (2010) 0.75
Stroke And Bleeding Risk Assessment: Where Are We Now? J Atr Fibrillation (2014) 0.75
LOWERING THE RISK FOR THROMBUS AND STROKE IN ATRIAL FIBRILLATION PATIENTS: Will Dabigatran Replace Warfarin? Clin Med Rev Vasc Health (2013) 0.75
Predicting thromboembolism and selecting patients for anticoagulant therapy in atrial fibrillation. J Am Coll Cardiol (2008) 0.75
Comparison between CHA2DS2-VASc and the new R2CHADS2 and ATRIA scores at predicting thromboembolic event in non-anticoagulated and anticoagulated patients with non-valvular atrial fibrillation. BMC Cardiovasc Disord (2015) 0.75
A Randomized Trial of Pharmacogenetic Warfarin Dosing in Naïve Patients with Non-Valvular Atrial Fibrillation. PLoS One (2015) 0.75
[Knowledge of guidelines for anticoagulation management of patients with atrial fibrillation]. Herzschrittmacherther Elektrophysiol (2015) 0.75
The meaning and use of the area under a receiver operating characteristic (ROC) curve. Radiology (1982) 79.76
Use and misuse of the receiver operating characteristic curve in risk prediction. Circulation (2007) 20.44
Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation. JAMA (2001) 16.98
Multiple biomarkers for the prediction of first major cardiovascular events and death. N Engl J Med (2006) 15.60
Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation. Analysis of pooled data from five randomized controlled trials. Arch Intern Med (1994) 10.26
Atrial fibrillation: a major contributor to stroke in the elderly. The Framingham Study. Arch Intern Med (1987) 8.09
National surveillance of emergency department visits for outpatient adverse drug events. JAMA (2006) 6.24
A risk score for predicting stroke or death in individuals with new-onset atrial fibrillation in the community: the Framingham Heart Study. JAMA (2003) 4.77
Warfarin use among ambulatory patients with nonvalvular atrial fibrillation: the anticoagulation and risk factors in atrial fibrillation (ATRIA) study. Ann Intern Med (1999) 4.54
Selecting patients with atrial fibrillation for anticoagulation: stroke risk stratification in patients taking aspirin. Circulation (2004) 4.45
An assessment of incremental coronary risk prediction using C-reactive protein and other novel risk markers: the atherosclerosis risk in communities study. Arch Intern Med (2006) 4.23
Anticoagulation therapy for stroke prevention in atrial fibrillation: how well do randomized trials translate into clinical practice? JAMA (2003) 4.13
Ximelagatran vs warfarin for stroke prevention in patients with nonvalvular atrial fibrillation: a randomized trial. JAMA (2005) 3.54
Coronary heart disease risk prediction in the Atherosclerosis Risk in Communities (ARIC) study. J Clin Epidemiol (2003) 3.40
Antithrombotic therapy in atrial fibrillation: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest (2004) 3.11
Advanced age, anticoagulation intensity, and risk for intracranial hemorrhage among patients taking warfarin for atrial fibrillation. Ann Intern Med (2004) 3.06
Hemorrhagic complications of anticoagulant treatment: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest (2004) 2.50
Death and disability from warfarin-associated intracranial and extracranial hemorrhages. Am J Med (2007) 2.16
Implications of stroke risk criteria on the anticoagulation decision in nonvalvular atrial fibrillation: the Anticoagulation and Risk Factors in Atrial Fibrillation (ATRIA) study. Circulation (2000) 2.09
Gender differences in the risk of ischemic stroke and peripheral embolism in atrial fibrillation: the AnTicoagulation and Risk factors In Atrial fibrillation (ATRIA) study. Circulation (2005) 1.66
Prognostic value of plasma von Willebrand factor and soluble P-selectin as indices of endothelial damage and platelet activation in 994 patients with nonvalvular atrial fibrillation. Circulation (2003) 1.52
Perindopril-based blood pressure-lowering reduces major vascular events in patients with atrial fibrillation and prior stroke or transient ischemic attack. Stroke (2005) 1.20
Factor V Leiden and risk of ischemic stroke in nonvalvular atrial fibrillation: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study. J Thromb Thrombolysis (2003) 1.20
Additive role of plasma von Willebrand factor levels to clinical factors for risk stratification of patients with atrial fibrillation. Stroke (2006) 1.11
Assessment of three schemes for stratifying stroke risk in patients with nonvalvular atrial fibrillation. Am J Med (2000) 1.02
Heart disease and stroke statistics--2012 update: a report from the American Heart Association. Circulation (2011) 31.98
Heart disease and stroke statistics--2013 update: a report from the American Heart Association. Circulation (2012) 30.79
Heart disease and stroke statistics--2011 update: a report from the American Heart Association. Circulation (2010) 30.07
Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med (2011) 28.99
Heart disease and stroke statistics--2014 update: a report from the American Heart Association. Circulation (2013) 28.02
Heart disease and stroke statistics--2015 update: a report from the American Heart Association. Circulation (2014) 22.74
Heart Disease and Stroke Statistics-2016 Update: A Report From the American Heart Association. Circulation (2015) 10.14
Population trends in the incidence and outcomes of acute myocardial infarction. N Engl J Med (2010) 8.28
Criteria for evaluation of novel markers of cardiovascular risk: a scientific statement from the American Heart Association. Circulation (2009) 8.11
The Chronic Renal Insufficiency Cohort (CRIC) Study: Design and Methods. J Am Soc Nephrol (2003) 7.79
Large-scale association analysis identifies new risk loci for coronary artery disease. Nat Genet (2012) 7.59
Body mass index and risk for end-stage renal disease. Ann Intern Med (2006) 7.56
FGF23 induces left ventricular hypertrophy. J Clin Invest (2011) 7.22
Effect of intensity of oral anticoagulation on stroke severity and mortality in atrial fibrillation. N Engl J Med (2003) 6.70
Executive summary: heart disease and stroke statistics--2014 update: a report from the American Heart Association. Circulation (2014) 6.55
Executive summary: heart disease and stroke statistics--2012 update: a report from the American Heart Association. Circulation (2012) 6.24
Executive summary: heart disease and stroke statistics--2013 update: a report from the American Heart Association. Circulation (2013) 6.13
Dialysis-requiring acute renal failure increases the risk of progressive chronic kidney disease. Kidney Int (2009) 5.28
Vitamin D therapy and cardiac structure and function in patients with chronic kidney disease: the PRIMO randomized controlled trial. JAMA (2012) 5.27
The "gender gap" in authorship of academic medical literature--a 35-year perspective. N Engl J Med (2006) 5.23
A new risk scheme to predict warfarin-associated hemorrhage: The ATRIA (Anticoagulation and Risk Factors in Atrial Fibrillation) Study. J Am Coll Cardiol (2011) 5.06
The effect of low-dose warfarin on the risk of stroke in patients with nonrheumatic atrial fibrillation. The Boston Area Anticoagulation Trial for Atrial Fibrillation Investigators. N Engl J Med (1990) 4.77
The net clinical benefit of warfarin anticoagulation in atrial fibrillation. Ann Intern Med (2009) 4.71
Cost-effectiveness of dabigatran compared with warfarin for stroke prevention in atrial fibrillation. Ann Intern Med (2010) 4.16
Chronic Renal Insufficiency Cohort (CRIC) Study: baseline characteristics and associations with kidney function. Clin J Am Soc Nephrol (2009) 4.16
Association of prehospital advanced airway management with neurologic outcome and survival in patients with out-of-hospital cardiac arrest. JAMA (2013) 4.14
Anticoagulation therapy for stroke prevention in atrial fibrillation: how well do randomized trials translate into clinical practice? JAMA (2003) 4.13
Risk factors for end-stage renal disease: 25-year follow-up. Arch Intern Med (2009) 4.05
Antithrombotic therapy in atrial fibrillation: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest (2008) 4.01
Reducing delay in seeking treatment by patients with acute coronary syndrome and stroke: a scientific statement from the American Heart Association Council on cardiovascular nursing and stroke council. Circulation (2006) 3.93
Effect of age on stroke prevention therapy in patients with atrial fibrillation: the atrial fibrillation investigators. Stroke (2009) 3.89
Defining patient complexity from the primary care physician's perspective: a cohort study. Ann Intern Med (2011) 3.83
Improved blood pressure control associated with a large-scale hypertension program. JAMA (2013) 3.80
Causes of death for patients with community-acquired pneumonia: results from the Pneumonia Patient Outcomes Research Team cohort study. Arch Intern Med (2002) 3.78
Long-term outcomes of surgical and nonsurgical management of lumbar spinal stenosis: 8 to 10 year results from the maine lumbar spine study. Spine (Phila Pa 1976) (2005) 3.67
Mortality among homeless adults in Boston: shifts in causes of death over a 15-year period. JAMA Intern Med (2013) 3.67
The effect of warfarin and intensity of anticoagulation on outcome of intracerebral hemorrhage. Arch Intern Med (2004) 3.63
A controlled trial of web-based diabetes disease management: the MGH diabetes primary care improvement project. Diabetes Care (2003) 3.57
Video decision support tool for advance care planning in dementia: randomised controlled trial. BMJ (2009) 3.55
Prevention of atrial fibrillation: report from a national heart, lung, and blood institute workshop. Circulation (2009) 3.50
Geographic variation in cardiovascular procedure use among Medicare fee-for-service vs Medicare Advantage beneficiaries. JAMA (2013) 3.30
Nonrecovery of kidney function and death after acute on chronic renal failure. Clin J Am Soc Nephrol (2009) 3.28
Phosphorus binders and survival on hemodialysis. J Am Soc Nephrol (2008) 3.26
Long-term outcomes of surgical and nonsurgical management of sciatica secondary to a lumbar disc herniation: 10 year results from the maine lumbar spine study. Spine (Phila Pa 1976) (2005) 3.17
Can patients be anticoagulated after intracerebral hemorrhage? A decision analysis. Stroke (2003) 3.12
Antithrombotic therapy in atrial fibrillation: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest (2004) 3.11
Tests of glycemia for the diagnosis of type 2 diabetes mellitus. Ann Intern Med (2002) 3.06
Advanced age, anticoagulation intensity, and risk for intracranial hemorrhage among patients taking warfarin for atrial fibrillation. Ann Intern Med (2004) 3.06
Patient-physician connectedness and quality of primary care. Ann Intern Med (2009) 3.01
Impact of activated vitamin D and race on survival among hemodialysis patients. J Am Soc Nephrol (2008) 2.96
Oral anticoagulants vs aspirin in nonvalvular atrial fibrillation: an individual patient meta-analysis. JAMA (2002) 2.94
Elevated blood pressure and risk of end-stage renal disease in subjects without baseline kidney disease. Arch Intern Med (2005) 2.90
Evidence of focal small-fiber axonal degeneration in complex regional pain syndrome-I (reflex sympathetic dystrophy). Pain (2006) 2.87
Executive Summary: Heart Disease and Stroke Statistics-2016 Update: A Report From the American Heart Association. Circulation (2016) 2.87
Presence and acquired origin of reduced recall for fear extinction in PTSD: results of a twin study. J Psychiatr Res (2008) 2.78
Rivaroxaban compared with warfarin in patients with atrial fibrillation and previous stroke or transient ischaemic attack: a subgroup analysis of ROCKET AF. Lancet Neurol (2012) 2.77
ADHD medications and risk of serious cardiovascular events in young and middle-aged adults. JAMA (2011) 2.77
Prediction of functional outcome in patients with primary intracerebral hemorrhage: the FUNC score. Stroke (2008) 2.72
Susceptibility locus for clinical and subclinical coronary artery disease at chromosome 9p21 in the multi-ethnic ADVANCE study. Hum Mol Genet (2008) 2.71
Racial variation in the prevalence of atrial fibrillation among patients with heart failure: the Epidemiology, Practice, Outcomes, and Costs of Heart Failure (EPOCH) study. J Am Coll Cardiol (2004) 2.68
The relationship between daily atrial tachyarrhythmia burden from implantable device diagnostics and stroke risk: the TRENDS study. Circ Arrhythm Electrophysiol (2009) 2.59
Incident atrial fibrillation and risk of end-stage renal disease in adults with chronic kidney disease. Circulation (2012) 2.56
Transplant nephrectomy improves survival following a failed renal allograft. J Am Soc Nephrol (2009) 2.56
Health-related quality of life and estimates of utility in chronic kidney disease. Kidney Int (2005) 2.54
Commonly used surrogates for baseline renal function affect the classification and prognosis of acute kidney injury. Kidney Int (2009) 2.53
An effective approach to high blood pressure control: a science advisory from the American Heart Association, the American College of Cardiology, and the Centers for Disease Control and Prevention. J Am Coll Cardiol (2013) 2.47
Vitamin D reduces left atrial volume in patients with left ventricular hypertrophy and chronic kidney disease. Am Heart J (2012) 2.42
Validation of a new brief physical activity survey among men and women aged 60-69 years. Am J Epidemiol (2006) 2.37
The unmet health care needs of homeless adults: a national study. Am J Public Health (2010) 2.36
Prevention of stroke and systemic embolism with rivaroxaban compared with warfarin in patients with non-valvular atrial fibrillation and moderate renal impairment. Eur Heart J (2011) 2.31
Estimates of current and future incidence and prevalence of atrial fibrillation in the U.S. adult population. Am J Cardiol (2013) 2.29
Risks for end-stage renal disease, cardiovascular events, and death in Hispanic versus non-Hispanic white adults with chronic kidney disease. J Am Soc Nephrol (2006) 2.26
HIV testing rates and outcomes in a South African community, 2001-2006: implications for expanded screening policies. J Acquir Immune Defic Syndr (2009) 2.24
Comparison of hyperglycemia, hypertension, and hypercholesterolemia management in patients with type 2 diabetes. Am J Med (2002) 2.19
Low frequency of treatment of osteoporosis among postmenopausal women following a fracture. Arch Intern Med (2003) 2.19
Impact of proteinuria and glomerular filtration rate on risk of thromboembolism in atrial fibrillation: the anticoagulation and risk factors in atrial fibrillation (ATRIA) study. Circulation (2009) 2.18
Factors associated with burnout during emergency medicine residency. Acad Emerg Med (2014) 2.18
Moving the tipping point: the decision to anticoagulate patients with atrial fibrillation. Circ Cardiovasc Qual Outcomes (2010) 2.17
Death and disability from warfarin-associated intracranial and extracranial hemorrhages. Am J Med (2007) 2.16